Oak Hill Advisors LP Invests $9.30 Million in Emergent BioSolutions Inc. (NYSE:EBS)

Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,113,338 shares of the biopharmaceutical company's stock, valued at approximately $9,296,000. Emergent BioSolutions makes up approximately 1.4% of Oak Hill Advisors LP's portfolio, making the stock its 6th biggest position. Oak Hill Advisors LP owned 2.05% of Emergent BioSolutions at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of EBS. State Street Corp lifted its stake in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock valued at $15,960,000 after buying an additional 1,713,200 shares in the last quarter. American Century Companies Inc. lifted its stake in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company's stock valued at $6,015,000 after buying an additional 623,201 shares in the last quarter. Vanguard Group Inc. lifted its stake in Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company's stock valued at $8,631,000 after buying an additional 436,911 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company's stock valued at $6,192,000 after buying an additional 316,700 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company's stock valued at $1,864,000 after buying an additional 253,960 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Rodman & Renshaw reaffirmed a "buy" rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark increased their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th.

Emergent BioSolutions Trading Down 1.8 %

Shares of EBS stock traded down $0.16 on Tuesday, reaching $8.60. 796,179 shares of the stock were exchanged, compared to its average volume of 3,218,158. The stock has a market cap of $465.95 million, a P/E ratio of -2.08 and a beta of 1.59. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a 50 day moving average of $9.39 and a two-hundred day moving average of $8.62. Emergent BioSolutions Inc. has a 1-year low of $1.42 and a 1-year high of $15.10.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.